Michael J. Paidas MD
Professor of Obstetrics, Gynecology, and Reproductive Sciences; Co- Director, Yale Women and Children's Center for Blood Disorders; Co- Director, National Hemophilia Foundation- Baxter Clinical Fellowship at Yale; Interim Chief, Section of Maternal Fetal Medicine; Interim Director, Maternal Fetal Medicine Fellowship; Interim Chief, Obstetrical Service, YNHH
Research Interests
Fetal loss; Preeclampsia; Fetal growth restriction; Preterm delivery; Abruption; Thromboembolism; Postpartum hemorrhage; Inherited and acquired thrombophilia; Alloimmune thrombocytopenia
Current Projects
“Adverse Pregnancy Outcome, Subsequent Cardiovascular&Thromboembolic Disease: Genetic Risk Determinants, Serum Biomarkers and the Role of Family History” The goals of this study are threefold: a) to determine whether women with adverse pregnancy outcomes or thromboembolism are at increased risk for chronic hypertension, coronary artery disease, or thromboembolism later in life; b) to determine whether specific genetic polymorphisms are associated with adverse pregnancy outcome; c) to determine association between family medical history and the occurrence of adverse pregnancy outcome.
“Preimplantation Factor (PIF) and decidual cell interaction” PIF is a newly discovered unique embryo derived peptide that has significant immune modulatory functions both in pregnancy and in autoimmune disorders. Preliminary data suggest it has significant diagnostic and therapeutic applications.
“A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin alfa in Hereditary Antithrombin (AT) Deficient Patients in High-Risk Situations for Thrombosis. This study is designed to evaluate the safety and effectiveness of recombinant human antithrombin (rhAT) in high risk settings for thrombosis in antithrombin deficient patients, such as the period of labor and birth.
“Determination of Antithrombin Antibodies in a Healthy Pregnant Population During the Peripartum Period.” This study is designed to determine the levels of antithrombin antibodies in the peripartum period and is a follow up study to a completed clinical trial using Atryn, recombinant antithrombin.
“A Proposal to Perform a Cost Benefit Analysis to Determine the Utility of Antenatal Administration of Atryn® in the Setting of Severe Preterm Preeclampsia”.
“A Phase IIIB Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum versus Without Speculum” Principal Investigator at Yale: Paidas MJ. This clinical trial will determine whether FFN specimen acquisition without a speculum is equivalent to FFN specimen acquisition using a specimen.
“KEEPS trial: Kronos Early Estrogen Prevention Study”. The KEEPS trial is a five-year, multicenter, randomized, placebo controlled, clinical trial aimed at providing prospective data on the risks and benefits of early menopausal hormone intervention, particularly as it relates to the progression of atherosclerosis. Dr. Paidas serves as Coagulation Consultant.
“Postpartum Hemorrhage Survey” This study is designed to determine current national trends in treating postpartum hemorrhage.
“Multigate Doppler with Global Acquisition and Signal Processing (G.A.S.P.) in the uteroplacental and fetal circulations.” This new non-invasive Doppler ultrasound technology is being applied to a variety of areas concerning women’s health, including early pregnancy assessment and gynecologic malignancy screening.
Research Summary
His research focuses especially on the prevention, detection and management of pregnancy complications, including fetal loss, preeclampsia, fetal growth restriction, preterm delivery, abruption, thromboembolism and postpartum hemorrhage. Hematologic disorders of particular interest for Dr. Paidas include inherited and acquired thrombophilias, hereditary antithrombin deficiency, and alloimmune thrombocytopenia.
Extensive Research Description
“Adverse Pregnancy Outcome, Subsequent Cardiovascular&Thromboembolic Disease: Genetic Risk Determinants, Serum Biomarkers and the Role of Family History” The goals of this study are threefold: a) to determine whether women with adverse pregnancy outcomes or thromboembolism are at increased risk for chronic hypertension, coronary artery disease, or thromboembolism later in life; b) to determine whether specific genetic polymorphisms are associated with adverse pregnancy outcome; c) to determine association between family medical history and the occurrence of adverse pregnancy outcome.
“Preimplantation Factor (PIF) and decidual cell interaction” PIF is a newly discovered unique embryo derived peptide that has significant immune modulatory functions both in pregnancy and in autoimmune disorders. Preliminary data suggest it has significant diagnostic and therapeutic applications.
“A Multicenter, Multinational Study to Assess the Safety and Efficacy of Antithrombin alfa in Hereditary Antithrombin (AT) Deficient Patients in High-Risk Situations for Thrombosis. This study is designed to evaluate the safety and effectiveness of recombinant human antithrombin (rhAT) in high risk settings for thrombosis in antithrombin deficient patients, such as the period of labor and birth.
“Determination of Antithrombin Antibodies in a Healthy Pregnant Population During the Peripartum Period.” This study is designed to determine the levels of antithrombin antibodies in the peripartum period and is a follow up study to a completed clinical trial using Atryn, recombinant antithrombin.
“A Proposal to Perform a Cost Benefit Analysis to Determine the Utility of Antenatal Administration of Atryn® in the Setting of Severe Preterm Preeclampsia”.
“A Phase IIIB Comparison of Fetal Fibronectin (fFN) Specimen Collection Methodologies: With Speculum versus Without Speculum” Principal Investigator at Yale: Paidas MJ. This clinical trial will determine whether FFN specimen acquisition without a speculum is equivalent to FFN specimen acquisition using a specimen.
“KEEPS trial: Kronos Early Estrogen Prevention Study”. The KEEPS trial is a five-year, multicenter, randomized, placebo controlled, clinical trial aimed at providing prospective data on the risks and benefits of early menopausal hormone intervention, particularly as it relates to the progression of atherosclerosis. Dr. Paidas serves as Coagulation Consultant.
“Postpartum Hemorrhage Survey” This study is designed to determine current national trends in treating postpartum hemorrhage.
“Multigate Doppler with Global Acquisition and Signal Processing (G.A.S.P.) in the uteroplacental and fetal circulations.” This new non-invasive Doppler ultrasound technology is being applied to a variety of areas concerning women’s health, including early pregnancy assessment and gynecologic malignancy screening.
Selected Publications
- Lykke J, Paidas MJ, Langhoff-Roos J. Recurring Complications in Second Pregnancy. Obstet Gynecol. 2009 Jun;113(6):1217-24.
- Lykke JA, Langhoff-Roos, Sibai BM, Funai E, Triche EW, Paidas MJ. Hypertensive pregnancy disorders and subsequent cardiovascular morbidity and type 2 diabetes mellitus in the mother. Hypertension. 2009 Jun;53(6):944-51.
- Rodger MA, Paidas M, Claire M, Middeldorp S, Kahn S, Martinelli I, Hague W, Rosene Montella K, Greer I. Inherited Thrombophilia and Pregnancy Complications Revisited. Obstet Gynecol. 2008 Aug;112(2):320-324.
- Paidas MJ, Urban G, Ku DW, Rebarber A, Lockwood CJ, Arkel YS. Elevated First Trimester Soluble Fibrin Polymer is Associated with Adverse Pregnancy Outcome in Thrombophilic Patients. Blood Coagul Fibrinolysis, 2008 Dec;19(8):824-6.
- Duhl AJ, Paidas MJ, Ural SH, Branch W, Casele H, Cox-Gill J, Hamersley SL, Hyers TM, Katz V, Kuhlmann R, Nutescu EA, Thorp JA, Zehnder JL; Pregnancy and Thrombosis Working Group.Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol. 2007 Nov;197(5):457.e1-21
- Paidas MJ, Ku DW, Lee MJ, Shah M, Thurston A, Lockwood CJ, Arkel YS. Protein Z, protein S levels are lower in patients with thrombophilia and subsequent pregnancy complications. J Thromb Haemost 2005; 3: 497-501.
